&nbsp;

Sep 2025

Drug

flutamide

Other Name(s): Euflex®

Quick Link(s):

Aug 2025

Drug

fulvestrant

Other Name(s): Faslodex®

Quick Link(s):

Aug 2025

Drug

anastrozole

Other Name(s): Arimidex®

Quick Link(s):

Jun 2025

Drug

abiraterone

Other Name(s): Zytiga®

Quick Link(s):

Aug 2024

Regimen

ANAS

Cancer Type:

Breast

Intent: Adjuvant

Funding:

ODB - General Benefit

anastrozole

Drugs Used:

anastrozole

Quick Link(s):

Regimen Monograph

Apr 2024

Regimen

ANAS

Cancer Type:

Breast,

Gynecologic,

Endometrial

Intent: Palliative

Funding:

ODB - General Benefit

anastrozole

Drugs Used:

anastrozole

Quick Link(s):

Regimen Monograph

Apr 2024

Regimen

FLVS

Cancer Type:

Breast

Intent: Palliative

Funding:

ODB - General Benefit

fulvestrant

Drugs Used:

fulvestrant

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

ABIRPRED

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

ODB - General Benefit

abiraterone

ODB - General Benefit

prednisone

Drugs Used:

abiraterone,

prednisone

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

FLTM

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

ODB - General Benefit

flutamide

Drugs Used:

flutamide

Quick Link(s):

Regimen Monograph

Oct 2016

Regimen

FC(PO)+R

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

ODB - General Benefit

cyclophosphamide - oral tablets

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

Drugs Used:

riTUXimab,

fludarabine (Unfunded),

cyclophosphamide,

riTUXimab (subcut)

Quick Link(s):

Regimen Monograph

Aug 2020

Regimen

FC(PO)+R

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Previously Untreated Chronic Lymphocytic Leukemia

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Second Line - Chronic Lymphocytic Leukemia

ODB Limited Use

fludarabine - For the first-line treatment of CLL in combination with rituximab (tablets; with or without cyclophosphamide)

ODB Limited Use

fludarabine - For second-line therapy of patients with CLL who have failed or are intolerant to chlorambucil (tablets)

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Previously Untreated Chronic Lymphocytic Leukemia

Drugs Used: